The state of Pennsylvania currently has 537 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Philadelphia, Pittsburgh, Hershey and Allentown.
BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy
Recruiting
The primary objective is to determine the feasibility of combining pembrolizumab with a single fraction radiation boost in patients with early/ operable breast cancer. The secondary objectives are to assess clinical response on pre- and post-treatment clinical, imaging, and histology exams, and to assess immune response on pre and post treatment blood and tissue samples by tracking change in Ki67 + CD8 T cells in peripheral blood and in extent of tumor infiltrating lymphocytes. A clinically sign... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2024
Locations: Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania
Conditions: Breast Cancer
STOP-HER2: Stopping Trastuzumab in HER2+ MBC
Recruiting
This study is being done to see if anti-HER2 treatment be safely stopped in patients with HER2-positive metastatic breast cancer (MBC) that have had exceptional response to treatment. Exceptional response" is considered as cancer progression being controlled for three years or more since starting anti-HER2 treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2024
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer
TERPS Trial for De Novo Oligometastic Prostate Cancer
Recruiting
This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
09/23/2024
Locations: Sidney Kimmel Cancer Center at Jefferson Health, Philadelphia, Pennsylvania +1 locations
Conditions: Prostate Cancer, Oligometastatic Disease
EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer
Recruiting
The purpose of this research study is to evaluate the outcomes of two standard of care group exercise regimens to increase muscle mass in women who have been treated with breast cancer.
Gender:
FEMALE
Ages:
Between 20 years and 89 years
Trial Updated:
09/20/2024
Locations: Allegheny General Hospital, Pittsburgh, Pennsylvania
Conditions: Breast Cancer, Breast Carcinoma in Situ, Breast Cancer Female
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
Recruiting
This research study is looking to see whether the combination of Dostarlimab and Niraparib plus Radiation Therapy (RT) is safe and effective in participants with metastatic triple negative breast cancer. The names of the study treatment involved in this study are: * Dostarlimab * Niraparib * Radiation Therapy (RT), which is given per standard of care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/19/2024
Locations: University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania
Conditions: Breast Cancer, Triple Negative Breast Cancer
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Recruiting
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations. P... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
09/13/2024
Locations: Philadelphia MultiService Center, Philadelphia, PA, Philadelphia, Pennsylvania
Conditions: Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L Mutations
Study of Inupadenant (EOS100850) with Chemotherapy As Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
Recruiting
The study will first determine the optimal dose of inupadenant to be given in combination with carboplatin and pemetrexed to patients that progressed after receiving first line anti-PD(L)1 treatment for locally advanced or metastatic non-small cell lung cancer. The efficacy and safety of the combination is then compared to standard of care carboplatin and pemetrexed in the same populations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/04/2024
Locations: Gettysburg Cancer Center, Gettysburg, Pennsylvania
Conditions: Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer
Recruiting
This study seeks to determine the clinical impact of Gene Expression Classifier (GEC) testing in prostate cancer care while also developing a pragmatic approach for improved GEC clinical use and future study.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
Conditions: Prostate Cancer
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Recruiting
A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: Lancaster General Hospital, Lancaster, Pennsylvania +1 locations
Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Recruiting
Up to 40 evaluable women with known or suspected epithelial ovarian, fallopian tube, or primary peritoneal cancer will participate in two different imaging cohorts. The Biodistribution cohort will include up to 4 patients and the Dynamic cohort will include up to 36 patients. Human dosimetry will be calculated from the Biodistribution cohort. The Dynamic cohort date will evaluate preliminary information on uptake of \[18F\]FTT in gynecological cancer and compare with PARP-1 activity in tissue.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/26/2024
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Detection of Genetic Markers of Lung Cancer
Recruiting
The purpose of this research study is to determine the genetic changes and immunologic changes that are involved in the development and progression of bronchogenic lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/22/2024
Locations: Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Lung Cancer
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
Recruiting
This is a non-randomized single-arm, two cohorts, phase II study of iadademstat in combination with weekly paclitaxel in patients with relapse/refractory SCLC or extrapulmonary G3 Neuroendocrine Carcinomas. A total of 42 patients with SCLC (21 patients) and G3 NEC (21 patients) will be enrolled (including those enrolled in the safety lead-in portion).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/22/2024
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Small-cell Lung Cancer, Neuroendocrine Carcinoma